Neuronetics posted preliminary, unaudited fourth-quarter 2025 revenue of $41.8 million and full-year revenue of $149.2 million, with positive operating cash flow of $0.9 million in the quarter and year-end cash of $34.1 million. On an adjusted pro forma basis that assumes its Greenbrook acquisition closed January 1, 2024 and strips out intercompany sales and shuttered clinics, Q4 revenue grew 23% and full-year revenue rose 15%. Segment detail underscores the strategic pivot: Q4 NeuroStar device and treatment-session revenue reached $18.3 million, up 9% pro forma, while clinic revenue climbed 37% pro forma to $23.5 million. For the year, NeuroStar revenue rose 0.9% pro forma to $62.2 million, and clinic revenue advanced 28% pro forma to $87.0 million. The company shipped 49 NeuroStar Advanced Therapy systems in Q4, and plans to report final results on March 17.
The numbers tell a clear story: vertical integration is now the growth engine. Modest device growth alongside robust clinic revenue suggests the value is migrating downstream to care delivery, where throughput, adherence, and payer mix determine margins. That shift brings operating complexity and working-capital needs that pure-play device models largely avoid, but it also creates recurring revenue, tighter control of clinical protocols, and a platform for real-world evidence that can influence coverage and guideline adoption. The central strategic question is whether a device-led provider ecosystem can scale profitably in mental health, where payer controls are stringent and patient engagement is variable.
This matters now because mental health demand is rising while the unit economics of advanced interventions remain fragile. Patients stand to gain from expanded access points offering NeuroStar TMS, esketamine, and combination modalities under one roof, potentially shortening time to an effective therapy after medication failure. Payers will weigh a more consolidated network that can standardize outcomes against the risk of procedure volume expansion; they will demand measurable, durable symptom improvement and clear care pathways to justify utilization. Referring psychiatrists and primary care physicians may find a simpler referral and feedback loop, but will expect evidence that integrated clinics improve remission rates, reduce polypharmacy, and limit relapse. Competitors across TMS hardware, independent clinic chains, and ketamine providers face a tougher landscape as Neuronetics aligns product, protocol, and patient funnel. The closure of non-performing clinics embedded in the pro forma set points to disciplined pruning—an early indicator that management is prioritizing density, payer fit, and throughput over raw footprint.
For Commercial leaders, the model reframes go-to-market from capital placement to capacity management and payer contracting. Success hinges on clinic-level occupancy, care coordination, and prior-authorization velocity as much as on sales coverage. For Medical Affairs, the network becomes a living RWE engine across MDD, comorbid anxiety in MDD, OCD adjunct use, and adolescent MDD, with an opportunity to publish outcomes that influence formularies and reduce step edits. If Neuronetics can demonstrate consistent response and remission in community settings, it can shift payer conversations from price to value and potentially secure broader policies or episode-based reimbursement aligned to measurement-based care.
The broader trend is unmistakable: medtechs are moving beyond hardware into care delivery to capture longitudinal value, control the patient journey, and generate decision-grade data. In a capital-thrifty market, that integration can be a defensible moat—but only if cash flow scales with clinic productivity rather than hardware cycles. The next proving points are same-store growth, capital-light site expansion, payer policy stability for TMS and esketamine, and evidence that system placements translate into sustained treatment volumes. The question for 2026 is whether Neuronetics can convert an encouraging mix shift into a repeatable, cash-generative playbook—before rivals consolidate their own device-plus-clinic models and lock in referral pathways.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
